Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 378

1.

Comprehensive Profiling of Rheumatoid Arthritis Antibody Repertoire.

Lo KC, Sullivan E, Bannen RM, Jin H, Rowe M, Li H, Pinapati RS, Cartwright AJ, Tan JC, Patel J, Keystone EC, Siminovitch KA.

Arthritis Rheumatol. 2019 Aug 26. doi: 10.1002/art.41089. [Epub ahead of print]

PMID:
31449733
2.

Toward Defining Primary and Secondary Nonresponse in Rheumatoid Arthritis Patients Treated with Anti-TNF: Results from the BioTRAC and OBRI Registries.

Keystone EC, Rampakakis E, Movahedi M, Cesta A, Stutz M, Sampalis JS, Nantel F, Maslova K, Bombardier C.

J Rheumatol. 2019 Jul 1. pii: jrheum.190102. doi: 10.3899/jrheum.190102. [Epub ahead of print]

PMID:
31263067
3.

Elucidating the endogenous synovial fluid proteome and peptidome of inflammatory arthritis using label-free mass spectrometry.

Mahendran SM, Keystone EC, Krawetz RJ, Liang K, Diamandis EP, Chandran V.

Clin Proteomics. 2019 May 30;16:23. doi: 10.1186/s12014-019-9243-3. eCollection 2019.

4.

Treatment strategies in early rheumatoid arthritis methotrexate management: Results from a prospective cohort.

Moura CS, Schieir O, Valois MF, Thorne C, Bartlett SJ, Pope JE, Hitchon CA, Boire G, Haraoui B, Hazlewood GS, Keystone EC, Tin D, Bykerk VP, Bernatsky S; Canadian Early Arthritis Cohort (CATCH) Investigators.

Arthritis Care Res (Hoboken). 2019 May 21. doi: 10.1002/acr.23927. [Epub ahead of print]

PMID:
31112011
5.

Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis.

Tanaka Y, Fautrel B, Keystone EC, Ortmann RA, Xie L, Zhu B, Issa M, Patel H, Gaich CL, de Bono S, Rooney TP, Taylor PC.

Ann Rheum Dis. 2019 Jul;78(7):890-898. doi: 10.1136/annrheumdis-2018-214529. Epub 2019 Apr 30.

6.

Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study.

van der Heijde D, Strand V, Tanaka Y, Keystone E, Kremer J, Zerbini CAF, Cardiel MH, Cohen S, Nash P, Song YW, Tegzová D, Gruben D, Wallenstein G, Connell CA, Fleischmann R; ORAL Scan Investigators.

Arthritis Rheumatol. 2019 Jun;71(6):878-891. doi: 10.1002/art.40803. Epub 2019 Apr 24.

7.

MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis.

Peterfy C, DiCarlo J, Emery P, Genovese MC, Keystone EC, Taylor PC, Schlichting DE, Beattie SD, Luchi M, Macias W.

J Rheumatol. 2019 Aug;46(8):887-895. doi: 10.3899/jrheum.171469. Epub 2019 Jan 15.

8.

ACPA and RF as predictors of sustained clinical remission in patients with rheumatoid arthritis: data from the Ontario Best practices Research Initiative (OBRI).

Pope JE, Movahedi M, Rampakakis E, Cesta A, Sampalis JS, Keystone E, Thorne C, Bombardier C.

RMD Open. 2018 Nov 5;4(2):e000738. doi: 10.1136/rmdopen-2018-000738. eCollection 2018. Erratum in: RMD Open. 2019 Sep 24;5(2):e000738corr1.

9.

A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population.

Kivitz AJ, Cohen S, Keystone E, van Vollenhoven RF, Haraoui B, Kaine J, Fan H, Connell CA, Bananis E, Takiya L, Fleischmann R.

Semin Arthritis Rheum. 2018 Dec;48(3):406-415. doi: 10.1016/j.semarthrit.2018.07.006. Epub 2018 Jul 19.

10.

Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis.

Keystone EC, Breedveld FC, Kupper H, Li Y, Florentinus S, Sainsbury I.

RMD Open. 2018 Jun 13;4(1):e000637. doi: 10.1136/rmdopen-2017-000637. eCollection 2018.

11.

Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6.

van Vollenhoven RF, Lee EB, Fallon L, Zwillich SH, Wilkinson B, Chapman D, DeMasi R, Keystone E.

Arthritis Care Res (Hoboken). 2019 Jan;71(1):71-79. doi: 10.1002/acr.23585.

12.

High Adherence to System-Level Performance Measures for Rheumatoid Arthritis in a National Early Arthritis Cohort Over Eight Years.

Barber CEH, Schieir O, Lacaille D, Marshall DA, Barnabe C, Hazlewood G, Thorne JC, Ahluwalia V, Bartlett SJ, Boire G, Haraoui B, Hitchon C, Keystone E, Tin D, Pope JE, Denning L, Bykerk VP; Canadian Early Arthritis Cohort Investigators.

Arthritis Care Res (Hoboken). 2018 Jun;70(6):842-850. doi: 10.1002/acr.23439. Epub 2018 Mar 25.

13.

Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial.

van Vollenhoven RF, Keystone EC, Strand V, Pacheco-Tena C, Vencovský J, Behrens F, Racewicz A, Zipp D, Rharbaoui F, Wolter R, Knierim L, Schmeidl R, Zhou X, Aigner S, Dälken B, Wartenberg-Demand A; TREAT2b study team.

Ann Rheum Dis. 2018 Apr;77(4):495-499. doi: 10.1136/annrheumdis-2017-212478. Epub 2018 Jan 17.

PMID:
29343509
14.

The Dorsal 4-finger Technique: A Novel Method to Examine Metacarpophalangeal Joints in Patients with Rheumatoid Arthritis.

Omair MA, Akhavan P, Naraghi A, Mittoo S, Xiong J, Weber D, Lin D, Weber M, Keystone EC.

J Rheumatol. 2018 Mar;45(3):329-334. doi: 10.3899/jrheum.161507. Epub 2018 Jan 15.

PMID:
29335348
15.

Corrigendum to "Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndrome" [Clin. Immunol. 168 (2016) 25-29].

Harris VM, Sharma R, Cavett J, Kurien BT, Liu K, Koelsch KA, Rasmussen A, Radfar L, Lewis D, Stone DU, Kaufman CE, Li S, Segal B, Wallace DJ, Weisman MH, Venuturupalli S, Kelly JA, Alarcon-Riquelme ME, Pons-Estel B, Jonsson R, Lu X, Gottenberg JE, Anaya JM, Cunninghame-Graham DS, Huang AJW, Brennan MT, Hughes P, Alevizos I, Miceli-Richard C, Keystone EC, Bykerk VP, Hirschfield G, Xie G, Siminovitch KA, Ng WF, Nordmark G, Bucher SM, Eriksson P, Omdal R, Rhodus NL, Rischmueller M, Rohrer M, Wahren-Herlenius M, Witte T, Mariette X, Lessard CJ, Harley JB, Sivils KL, Scofield RH.

Clin Immunol. 2018 Feb;187:137-138. doi: 10.1016/j.clim.2017.11.012. Epub 2017 Dec 7. No abstract available.

PMID:
29195081
16.

Overweight, Obesity, and the Likelihood of Achieving Sustained Remission in Early Rheumatoid Arthritis: Results From a Multicenter Prospective Cohort Study.

Schulman E, Bartlett SJ, Schieir O, Andersen KM, Boire G, Pope JE, Hitchon C, Jamal S, Thorne JC, Tin D, Keystone EC, Haraoui B, Goodman SM, Bykerk VP; CATCH Investigators.

Arthritis Care Res (Hoboken). 2018 Aug;70(8):1185-1191. doi: 10.1002/acr.23457. Epub 2018 Jul 13.

17.

Early Rheumatoid Arthritis Presentation, Treatment, and Outcomes in Aboriginal Patients in Canada: A Canadian Early Arthritis Cohort Study Analysis.

Nagaraj S, Barnabe C, Schieir O, Pope J, Bartlett SJ, Boire G, Keystone E, Tin D, Haraoui B, Thorne JC, Bykerk VP, Hitchon C; Canadian Early Arthritis Cohort Study Investigators.

Arthritis Care Res (Hoboken). 2018 Aug;70(8):1245-1250. doi: 10.1002/acr.23470.

18.

Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone.

Keystone EC, Breedveld FC, van der Heijde D, van Vollenhoven RF, Emery P, Smolen JS, Sainsbury I, Florentinus S, Kupper H, Chen K, Kavanaugh A.

RMD Open. 2017 Sep 26;3(2):e000445. doi: 10.1136/rmdopen-2017-000445. eCollection 2017.

19.

Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis.

Keystone EC, Genovese MC, Schlichting DE, de la Torre I, Beattie SD, Rooney TP, Taylor PC.

J Rheumatol. 2018 Jan;45(1):14-21. doi: 10.3899/jrheum.161161. Epub 2017 Aug 15.

20.

Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.

Keystone EC, Taylor PC, Tanaka Y, Gaich C, DeLozier AM, Dudek A, Zamora JV, Cobos JAC, Rooney T, Bono S, Arora V, Linetzky B, Weinblatt ME.

Ann Rheum Dis. 2017 Nov;76(11):1853-1861. doi: 10.1136/annrheumdis-2017-211259. Epub 2017 Aug 10.

21.

Rare X Chromosome Abnormalities in Systemic Lupus Erythematosus and Sjögren's Syndrome.

Sharma R, Harris VM, Cavett J, Kurien BT, Liu K, Koelsch KA, Fayaaz A, Chaudhari KS, Radfar L, Lewis D, Stone DU, Kaufman CE, Li S, Segal B, Wallace DJ, Weisman MH, Venuturupalli S, Kelly JA, Pons-Estel B, Jonsson R, Lu X, Gottenberg JE, Anaya JM, Cunninghame-Graham DS, Huang AJW, Brennan MT, Hughes P, Alevizos I, Miceli-Richard C, Keystone EC, Bykerk VP, Hirschfield G, Nordmark G, Bucher SM, Eriksson P, Omdal R, Rhodus NL, Rischmueller M, Rohrer M, Wahren-Herlenius M, Witte T, Alarcón-Riquelme M, Mariette X, Lessard CJ, Harley JB, Ng WF, Rasmussen A, Sivils KL, Scofield RH.

Arthritis Rheumatol. 2017 Nov;69(11):2187-2192. doi: 10.1002/art.40207. Epub 2017 Oct 12.

22.

Triple Therapy Versus Biologic Therapy for Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis.

Bansback N, Phibbs CS, Sun H, O'Dell JR, Brophy M, Keystone EC, Leatherman S, Mikuls TR, Anis AH; CSP 551 RACAT Investigators.

Ann Intern Med. 2017 Jul 4;167(1):8-16. doi: 10.7326/M16-0713. Epub 2017 May 30.

PMID:
28554192
23.

Benefit of biologics initiation in moderate versus severe rheumatoid arthritis: evidence from a United States registry.

Kavanaugh A, Keystone E, Greenberg JD, Reed GW, Griffith JM, Friedman AW, Saunders KC, Ganguli A.

Rheumatology (Oxford). 2017 Jul 1;56(7):1095-1101. doi: 10.1093/rheumatology/kex042.

PMID:
28340006
24.

Thresholds for the 28-joint disease activity score (DAS28) using C-reactive protein are lower compared to DAS28 using erythrocyte sedimentation rate in early rheumatoid arthritis.

Kuriya B, Schieir O, Lin D, Xiong J, Pope J, Boire G, Haraoui B, Thorne JC, Tin D, Hitchon C, Jamal S, Keystone E, Bykerk VP; CATCH Investigators.

Clin Exp Rheumatol. 2017 Sep-Oct;35(5):799-803. Epub 2017 Mar 23.

PMID:
28339365
25.

Baricitinib in rheumatoid arthritis: evidence-to-date and clinical potential.

Kuriya B, Cohen MD, Keystone E.

Ther Adv Musculoskelet Dis. 2017 Feb;9(2):37-44. doi: 10.1177/1759720X16687481. Epub 2017 Jan 23. Review.

26.

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.

Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, Yakushin S, Ishii T, Emoto K, Beattie S, Arora V, Gaich C, Rooney T, Schlichting D, Macias WL, de Bono S, Tanaka Y.

N Engl J Med. 2017 Feb 16;376(7):652-662. doi: 10.1056/NEJMoa1608345.

27.

The effect of rheumatoid arthritis-associated autoantibodies on the incidence of cardiovascular events in a large inception cohort of early inflammatory arthritis.

Barra LJ, Pope JE, Hitchon C, Boire G, Schieir O, Lin D, Thorne CJ, Tin D, Keystone EC, Haraoui B, Jamal S, Bykerk VP; CATCH group.

Rheumatology (Oxford). 2017 May 1;56(5):768-776. doi: 10.1093/rheumatology/kew474.

PMID:
28073956
28.

Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis.

Kremer JM, Genovese MC, Keystone E, Taylor PC, Zuckerman SH, Ruotolo G, Schlichting DE, Crotzer VL, Nantz E, Beattie SD, Macias WL.

Arthritis Rheumatol. 2017 May;69(5):943-952. doi: 10.1002/art.40036.

29.

Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.

Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Zhou Y, Goldstein N, Braun J.

J Rheumatol. 2016 Dec;43(12):2120-2130. Epub 2016 Nov 1.

30.

Rituximab for Rheumatoid Arthritis.

Cohen MD, Keystone E.

Rheumatol Ther. 2015 Dec;2(2):99-111. Epub 2015 Aug 19. Review.

31.

Predicting Low Disease State and Remission in Early Rheumatoid Arthritis in the First Six Months, Comparing the Simplified Disease Activity Index and European League Against Rheumatism Response Measures: Results From an Early Arthritis Cohort.

Omair MA, Keystone E, Bykerk V, Lin D, Xiong J, Sun Y, Boire G, Thorne JC, Tin D, Pope J, Hitchon C, Haraoui B, Akhavan PS; Canadian Early Arthritis Cohort Investigators.

Arthritis Care Res (Hoboken). 2017 May;69(5):737-741. doi: 10.1002/acr.22983. Epub 2017 Apr 7.

32.
33.

Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies.

Fleischmann R, Kremer J, Tanaka Y, Gruben D, Kanik K, Koncz T, Krishnaswami S, Wallenstein G, Wilkinson B, Zwillich SH, Keystone E.

Int J Rheum Dis. 2016 Dec;19(12):1216-1225. doi: 10.1111/1756-185X.12901. Epub 2016 Jul 25. Review.

34.

High remission and low relapse with prolonged intensive DMARD therapy in rheumatoid arthritis (PRINT): A multicenter randomized clinical trial.

Li R, Zhao JX, Su Y, He J, Chen LN, Gu F, Zhao C, Deng XR, Zhou W, Hao YJ, Xue Y, Liu HX, Zhao Y, Zou QH, Liu XY, Zhu P, Sun LY, Zhang ZL, Zou HJ, Li XF, Liu Y, Fang YF, Keystone E, McInnes IB, Li ZG.

Medicine (Baltimore). 2016 Jul;95(28):e3968. doi: 10.1097/MD.0000000000003968.

35.

A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy.

Kremer JM, Emery P, Camp HS, Friedman A, Wang L, Othman AA, Khan N, Pangan AL, Jungerwirth S, Keystone EC.

Arthritis Rheumatol. 2016 Dec;68(12):2867-2877. doi: 10.1002/art.39801.

36.

Self-reported comorbidity is common in early inflammatory arthritis and associated with poorer function and worse arthritis disease outcomes: results from the Canadian Early Arthritis Cohort.

Hitchon CA, Boire G, Haraoui B, Keystone E, Pope J, Jamal S, Tin D, Thorne C, Bykerk VP; CATCH investigators.

Rheumatology (Oxford). 2016 Oct;55(10):1751-62. doi: 10.1093/rheumatology/kew061. Epub 2016 Jun 21.

PMID:
27330161
37.

Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set.

Bykerk VP, Bingham CO, Choy EH, Lin D, Alten R, Christensen R, Furst DE, Hewlett S, Leong A, March L, Woodworth T, Boire G, Haraoui B, Hitchon C, Jamal S, Keystone EC, Pope J, Tin D, Thorne JC, Bartlett SJ.

RMD Open. 2016 May 26;2(1):e000225. doi: 10.1136/rmdopen-2015-000225. eCollection 2016.

38.

Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndrome.

Harris VM, Sharma R, Cavett J, Kurien BT, Liu K, Koelsch KA, Rasmussen A, Radfar L, Lewis D, Stone DU, Kaufman CE, Li S, Segal B, Wallace DJ, Weisman MH, Venuturupalli S, Kelly JA, Alarcon-Riquelme ME, Pons-Estel B, Jonsson R, Lu X, Gottenberg JE, Anaya JM, Cunninghame-Graham DS, Huang AJW, Brennan MT, Hughes P, Alevizos I, Miceli-Richard C, Keystone EC, Bykerk VP, Hirschfield G, Xie G, Siminovitch KA, Ng WF, Nordmark G, Bucher SM, Eriksson P, Omdal R, Rhodus NL, Rischmueller M, Rohrer M, Wahren-Herlenius M, Witte T, Mariette X, Lessard CJ, Harley JB, Sivils KL, Scofield RH.

Clin Immunol. 2016 Jul;168:25-29. doi: 10.1016/j.clim.2016.04.002. Epub 2016 Apr 22. Erratum in: Clin Immunol. 2017 Nov 28;:.

39.

Reduction in Serum Uric Acid May Be Related to Methotrexate Efficacy in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort (CATCH).

Lee JJ, Bykerk VP, Dresser GK, Boire G, Haraoui B, Hitchon C, Thorne C, Tin D, Jamal S, Keystone EC, Pope JE.

Clin Med Insights Arthritis Musculoskelet Disord. 2016 Apr 4;9:37-43. doi: 10.4137/CMAMD.S38092. eCollection 2016.

40.

Fibrocyte and T cell interactions promote disease pathogenesis in rheumatoid arthritis.

Galligan CL, Keystone EC, Fish EN.

J Autoimmun. 2016 May;69:38-50. doi: 10.1016/j.jaut.2016.02.008. Epub 2016 Mar 3.

PMID:
26948996
41.

X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sjögren's Syndrome.

Liu K, Kurien BT, Zimmerman SL, Kaufman KM, Taft DH, Kottyan LC, Lazaro S, Weaver CA, Ice JA, Adler AJ, Chodosh J, Radfar L, Rasmussen A, Stone DU, Lewis DM, Li S, Koelsch KA, Igoe A, Talsania M, Kumar J, Maier-Moore JS, Harris VM, Gopalakrishnan R, Jonsson R, Lessard JA, Lu X, Gottenberg JE, Anaya JM, Cunninghame-Graham DS, Huang AJW, Brennan MT, Hughes P, Illei GG, Miceli-Richard C, Keystone EC, Bykerk VP, Hirschfield G, Xie G, Ng WF, Nordmark G, Eriksson P, Omdal R, Rhodus NL, Rischmueller M, Rohrer M, Segal BM, Vyse TJ, Wahren-Herlenius M, Witte T, Pons-Estel B, Alarcon-Riquelme ME, Guthridge JM, James JA, Lessard CJ, Kelly JA, Thompson SD, Gaffney PM, Montgomery CG, Edberg JC, Kimberly RP, Alarcón GS, Langefeld CL, Gilkeson GS, Kamen DL, Tsao BP, McCune WJ, Salmon JE, Merrill JT, Weisman MH, Wallace DJ, Utset TO, Bottinger EP, Amos CI, Siminovitch KA, Mariette X, Sivils KL, Harley JB, Scofield RH.

Arthritis Rheumatol. 2016 May;68(5):1290-1300. doi: 10.1002/art.39560.

42.

Making smart investment decisions in clinical research.

Bansback N, Keystone E, O'Dell J, Phibbs CS, Hannagan K, Brophy M, Anis A.

Trials. 2015 Dec 29;16:590. doi: 10.1186/s13063-015-1123-1.

43.

Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial.

Keystone EC, Genovese MC, Hall S, Bae SC, Han C, Gathany TA, Xu S, Zhou Y, Leu JH, Hsia EC.

J Rheumatol. 2016 Feb;43(2):298-306. doi: 10.3899/jrheum.150712. Epub 2015 Dec 15.

PMID:
26669912
44.

Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody.

Isaacs JD, Cutolo M, Keystone EC, Park W, Braun J.

J Intern Med. 2016 Jan;279(1):41-59. doi: 10.1111/joim.12432. Epub 2015 Sep 25. Review.

45.

Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis.

Keystone EC, Pope JE, Thorne JC, Poulin-Costello M, Phan-Chronis K, Vieira A, Haraoui B; CAMEO Investigators.

Rheumatology (Oxford). 2016 Feb;55(2):327-34. doi: 10.1093/rheumatology/kev338. Epub 2015 Sep 11.

46.

Missing Anticitrullinated Protein Antibody Does Not Affect Short-term Outcomes in Early Inflammatory Arthritis: From the Canadian Early Arthritis Cohort.

Shu J, Bykerk VP, Boire G, Haraoui B, Hitchon C, Thorne JC, Tin D, Keystone EC, Pope JE; CATCH Investigators.

J Rheumatol. 2015 Nov;42(11):2023-8. doi: 10.3899/jrheum.150260. Epub 2015 Sep 1.

PMID:
26329342
47.

Heterogeneous Disease Trajectories Explain Variable Radiographic, Function and Quality of Life Outcomes in the Canadian Early Arthritis Cohort (CATCH).

Barnabe C, Sun Y, Boire G, Hitchon CA, Haraoui B, Thorne JC, Tin D, van der Heijde D, Curtis JR, Jamal S, Pope JE, Keystone EC, Bartlett S, Bykerk VP; CATCH Investigators.

PLoS One. 2015 Aug 24;10(8):e0135327. doi: 10.1371/journal.pone.0135327. eCollection 2015.

48.

The influence of age at disease onset on disease activity and disability: results from the Ontario Best Practices Research Initiative.

Ruban TN, Jacob B, Pope JE, Keystone EC, Bombardier C, Kuriya B.

Clin Rheumatol. 2016 Mar;35(3):759-63. doi: 10.1007/s10067-015-3031-x. Epub 2015 Aug 6.

PMID:
26245721
49.

Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre-Specified Analysis of Two Phase III Trials.

Combe B, Furst DE, Keystone EC, van der Heijde D, Luijtens K, Ionescu L, Goel N, Emery P.

Arthritis Care Res (Hoboken). 2016 Mar;68(3):299-307. doi: 10.1002/acr.22676.

50.

14-3-3η Autoantibodies: Diagnostic Use in Early Rheumatoid Arthritis.

Maksymowych WP, Boire G, van Schaardenburg D, Wichuk S, Turk S, Boers M, Siminovitch KA, Bykerk V, Keystone E, Tak PP, van Kuijk AW, Landewé R, van der Heijde D, Murphy M, Marotta A.

J Rheumatol. 2015 Sep;42(9):1587-94. doi: 10.3899/jrheum.141385. Epub 2015 Jul 15.

PMID:
26178283

Supplemental Content

Loading ...
Support Center